Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson’s Disease
Rita Maria Concetta Di Martino(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Federica Belluti(University of Bologna), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Letizia Pruccoli(University of Bologna), Elia Di Schiavi(National Research Council), Angela Rampa(University of Bologna), Andrea Tarozzi(Istituto Nazionale Biostrutture e Biosistemi), Alessandra Bisi(University of Bologna), Francesca Seghetti(University of Bologna), Silvia Gobbi(University of Bologna), Maria Paglione(Leman University), Concepción Pérez(Instituto de Química Médica), Loreto Martínez‐González(Consejo Superior de Investigaciones Científicas)
Cited by 58
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
Deuterium in drug discovery: progress, opportunities and challenges
|Nature Reviews Drug Discovery|2023|458
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair
|Nature Genetics|2009|417
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348